title: Serum miR-224 reflects stage of hepatocellular carcinoma and predicts survival.
abstract: BACKGROUND
  In our previous study, we conducted a systematic screening of miRNA to identify potential serum biomarkers for predicting venous metastasis and survival in patients with hepatocellular carcinoma (HCC). miR-224 was one of the differentially expressed miRNAs. This study aimed to confirm whether serum miR-224 level is associated with the presence of venous metastasis and survival.
  
  
  METHODS
  TaqMan miRNA probe was used to perform qRT-PCR assays to evaluate the expression of serum miR-224 in a cohort of 182 HCC patients.
  
  
  RESULTS
  Patients with high miR-224 serum level showed poor survival compared to that with low miR-224 serum level (HR 1.985; 95% CI, 1.08, 3.65, P=0.027). The serum miR-224 levels were significantly higher in the BCLC stage C patients compared with the stage B patients (P=0.005). In further analysis, significant difference of serum miR-224 expression level was observed when patients grouped by the status of PVTT but not the status of extra-liver metastasis (P=0.013 and P=0.091). Serum levels of miR-224 showed significant relation with parameters of liver damage and serum AFP.
  
  
  CONCLUSIONS
  Serum miR-224 might be BCLC stage dependent. It can reflect the status of tumor and liver damage. It was an independent predictor for the survival of HCC patients.
authors: Department of Integrative Medicine, Fudan University Shanghai Cancer Center, 270 Dongan Road, Shanghai 200032, China ; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
authors: Li-ping
authors: LP
authors: Zhuang
authors: Department of Integrative Medicine, Fudan University Shanghai Cancer Center, 270 Dongan Road, Shanghai 200032, China ; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
authors: Zhi-qiang
authors: ZQ
authors: Meng
mesh_terms: D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000097:blood* / Q000453:epidemiology / Q000401:mortality* / Q000473:pathology; D015331:Cohort Studies; D005260:Female; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008113:Liver Neoplasms / Q000097:blood* / Q000453:epidemiology / Q000401:mortality* / Q000473:pathology; D008297:Male; D035683:MicroRNAs / Q000097:blood*; D008875:Middle Aged; D009367:Neoplasm Staging; D012189:Retrospective Studies
chemical_list: D035683:MicroRNAs